The U.S. Food and Drug Administration (FDA) published a March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.
Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.
For more information about various 新澳门六合彩官网®(新澳门六合彩官网®) AI-specific initiatives, visit the ®. For more information about FDA oversight and digital health policy, contact Michael Peters, 新澳门六合彩官网 Senior Government Affairs Director.